All In Biotech

Drug Trial Radar · NCT03439345

Lowering Events in Non-proliferative Retinopathy in Scotland

A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes

Last checked: Nov 20, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,151 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,151

Actual

Start

Jul 23, 2018

Primary completion

Nov 17, 2023

Study completion Feb 16, 2024

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute for Health Research, United Kingdom; University of Glasgow; University of Aberdeen; University of Dundee; University of Edinburgh; NHS Scotland Diabetic Retinopathy Screening Collaborative
First posted
Feb 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

LENS is a streamlined multicentre randomised placebo-controlled parallel-group trial investigating the effect of fenofibrate treatment on the progression of diabetic retinopathy/maculopathy.

Conditions

  • Diabetic Retinopathy

Interventions

  • Fenofibrate 145 mgDrug

    One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)

  • Placebo Oral TabletDrug

    One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Progression to Referable Diabetic Retinopathy or Maculopathy, or TreatmentTime frame: 4.0 years (interquartile range, 3.6 to 4.3) years

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • NHS Grampian

    Aberdeen, United Kingdom

  • NHS Lanarkshire

    Airdrie, United Kingdom

  • NHS Ayrshire and Arran

    Ayr, United Kingdom

  • NHS Dumfries and Galloway

    Dumfries, United Kingdom

  • NHS Tayside

    Dundee, United Kingdom

  • NHS Fife

    Dunfermline, United Kingdom

  • NHS Lanarkshire

    East Kilbride, United Kingdom

  • NHS Lothian

    Edinburgh, United Kingdom

  • NHS Greater Glasgow and Clyde

    Glasgow, United Kingdom

  • NHS Highland

    Inverness, United Kingdom

  • NHS Ayrshire and Arran

    Kilmarnock, United Kingdom

  • NHS Fife

    Kirkcaldy, United Kingdom

  • NHS Forth Valley

    Larbert, United Kingdom

  • NHS Borders

    Melrose, United Kingdom

  • NHS Tayside

    Perth, United Kingdom

  • NHS Lanarkshire

    Wishaw, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.